

Fluid Expansion As Supportive Therapy in critically ill African children

Submission date 29/11/2008	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 21/01/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 17/06/2019	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Kathryn Maitland

Contact details
KEMRI Wellcome Trust Unit
Kilifi
Kenya
P.O Box 230-801
+254 41 7522063
kmaitland@kilifi.kemri-wellcome.org

Additional identifiers

Protocol serial number
MRC ref: G0801439

Study information

Scientific Title
A randomised trial of fluid resuscitation strategies in African children with severe febrile illness and clinical evidence of impaired perfusion

Acronym

FEAST

Study objectives

In hospitals throughout sub-Saharan Africa, mortality from malaria and other severe infections in childhood remains at 15-30%, with over 50% of deaths occurring within 24 hours of admission. Currently, antimalarial and antimicrobial drugs are the mainstay of treatment, with little consideration being given to the use of adjunctive supportive therapies. There is considerable debate about the degree to which intravascular volume depletion (hypovolaemia) contributes to the pathophysiology of malaria and other severe infections, and clinical practice varies widely across the continent. To resolve the continuing uncertainty, this multi-centre randomised clinical trial will evaluate different fluid resuscitation strategies in children presenting to hospital with severe febrile illness and clinical evidence of impaired perfusion, with the intention of generating data of practical value to clinicians working in resource-poor settings in Africa.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Imperial College Research Ethics Committee (UK), approved in August 2008 (ref: ICREC_8_1_1)
2. Kenya Medical Research Institute (KEMRI) National Ethics Review Committee (Kenya), approved in July 2008 (ref: SCC 1355)
3. National Ethics Review Committee, Makerere University (Uganda) approved in April 2008
4. NIMRI Ethics Review Board (Tanzania), approved in September 2008 (ref: 748)

Study design

Open randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Severe illness with shock due to sepsis or severe malaria

Interventions

This is a three-arm randomised open controlled trial comparing two active fluid resuscitation strategies to control (no bolus). 2,880 children will be assigned in a ratio of 1:1:1 to one of the three fluid management arms; 144 with decompensated shock will be randomised to human albumin solution (HAS) or saline.

Three resuscitation strategies:

1. Immediate volume resuscitation with normal (0.9%) saline
2. Immediate volume expansion with 5% human albumin solution (HAS)
3. No immediate volume expansion (control)

Children will be assessed for neurological deficit at 28 days from date of randomisation. A further assessment will be conducted at six months only in children with a persistent neurological sequelae at 28 days.

Please use the following contact details to request a patient information sheet:

Study Coordinator: Dr Mukami Mbogo

KEMRI Wellcome Trust Programme

P.O. Box 230-80108

Kilifi

Kenya

Tel: +254 41 7522063

Fax: +254 41 7522390

Email: mmbogo@kilifi.kemri-wellcome.org

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

In-hospital mortality at 48 hours after randomisation.

Key secondary outcome(s)

1. Mortality at 4 weeks after randomisation
2. Mortality or neurological sequelae at 4 weeks after randomisation
3. Neurological sequelae at 4 weeks after randomisation
4. Persistent neurological sequelae at 6 months after randomisation
5. Development of hypotensive shock within 48 hours of randomisation
6. Adverse event within 48 hours of randomisation (pulmonary oedema, intracranial hypertension, severe allergic reaction in those receiving albumin)

Completion date

01/12/2011

Eligibility

Key inclusion criteria

Children (both males and females, age range >60 days and <12 years) with severe illness and clinical evidence of impaired perfusion in whom there is uncertainty as to the benefits of immediate fluid resuscitation and what type of fluid to give.

Severe illness and impaired perfusion defined as follows:

1. Severe illness: one or more of the following:
 - 1.1. Impaired consciousness: prostration or coma
 - 1.2. Respiratory distress

Prostration: inability to sit unsupported, or to breast feed if < 9months

Coma: inability to localise a painful stimulus

Respiratory distress: Deep breathing or increased work of breathing

2. Impaired perfusion: one or more of the following:

- 2.1. Capillary refill time >2s

- 2.2. Lower limb temperature gradient

2.3. Weak radial pulse volume

2.4. Severe tachycardia

Severe tachycardia: if <12 months: >180 bpm; 12 months to 5 years: >160 bpm; >5 years: >140 bpm

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

60 days

Upper age limit

12 years

Sex

All

Total final enrolment

3141

Key exclusion criteria

One or more of the following at admission:

1. Severe acute malnutrition
2. Gastroenteritis
3. Conditions where intravascular volume expansion is contraindicated, namely chronic renal failure, pulmonary oedema
4. Non-infectious causes of severe illness: trauma, burns, intoxication
5. Children who have already received volume expansion using an isotonic volume expander during the current illness

Severe malnutrition: visible severe wasting and/or kwashiorkor

Gastroenteritis: >3 watery stools in previous 24 hours

Pulmonary oedema: oxygen saturation <90% on pulse oximetry plus bilateral basal crepitations

Date of first enrolment

15/12/2008

Date of final enrolment

01/12/2011

Locations

Countries of recruitment

Kenya

Tanzania

Uganda

Study participating centre
KEMRI Wellcome Trust Unit
Kilifi
Kenya
P.O Box 230-801

Sponsor information

Organisation
Imperial College of Science, Technology and Medicine (UK)

ROR
<https://ror.org/041kmwe10>

Funder(s)

Funder type
Government

Funder Name
Medical Research Council (UK) (ref: G0801439)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	30/06/2011		Yes	No
Results article	results	14/03/2013		Yes	No
Results article	results	01/07/2019	17/06/2019	Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes